Mirati Therapeutics Inc. | Mutual Funds
Mutual Funds that own Mirati Therapeutics Inc.
Vanguard Total Stock Market Index Fund
714,101
2.21%
0
0.01%
07/31/2018
SPDR S&P Biotech ETF
673,944
2.08%
1,734
0.65%
09/06/2018
Fidelity Series Small Cap Opportunities Fund
545,200
1.69%
33,400
0.48%
04/30/2018
Fidelity Small Cap Growth Fund
460,055
1.42%
460,055
0.56%
04/30/2018
Vanguard Extended Market Index Fund
420,800
1.3%
4,500
0.03%
07/31/2018
Fidelity Select Biotechnology Portfolio
410,188
1.27%
40,000
0.25%
07/31/2018
iShares Russell 2000 ETF
379,042
1.17%
-201
0.04%
09/06/2018
Prudential Jennison Health Sciences Fund
316,359
0.98%
0
0.7%
07/31/2018
Janus Global Life Sciences Fund
297,055
0.92%
297,055
0.41%
06/30/2018
Fidelity Advisor Biotechnology Fund
262,667
0.81%
148,547
0.51%
07/31/2018
| Address |
9393 Towne Centre Drive
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.mirati.com |
| Updated |
07/08/2019 |
| Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA. |
